Reviewed by Dr. Ankeet Choxi and Jarred Mait, MD
In regenerative medicine, conversations around cell counts and treatment pricing often take center stage. Patients are frequently presented with numbers – millions of cells, multiple vials, expanded doses – without always being given visibility into how those cells were produced.
One of the less visible, but clinically relevant, factors behind both cost and quality is cell passage.
Understanding how laboratories expand cells – and why higher passages can reduce costs – offers important context for evaluating treatment protocols, particularly when comparing seemingly similar therapies across different providers.
What Does “Cell Passage” Actually Mean?
In laboratory settings, cell passage refers to the process of growing cells in culture and periodically transferring them to new environments to continue expansion.
The process begins with an initial cell population, often referred to as Passage 0. As cells grow and multiply, they are split and re-cultured:
- Passage 1: First expansion
- Passage 2: Further expansion
- Passage 3 and beyond: Continued replication cycles
Each passage represents another round of growth, where the total number of cells increases – sometimes exponentially.
From a production standpoint, this process allows laboratories to scale biologic materials efficiently. A relatively small initial sample can be expanded into a much larger volume over multiple passages.
Why Increasing Cell Passages Reduces Cost
The economic logic behind higher passage expansion is straightforward.
At earlier passages, cell populations are smaller and require more starting material. This often means:
- More donor material or extraction procedures
- Higher processing costs per usable cell
- Lower overall yield
As cells are expanded through additional passages, the yield increases significantly. This allows laboratories to:
- Produce larger quantities from a single starting sample
- Lower the cost per million cells
- Distribute material across more treatment doses
From a business perspective, higher passage expansion creates efficiency. It enables broader scalability and supports pricing models that may appear more accessible at the surface level.
However, cost efficiency and biological performance are not always aligned.
The Biological Trade-Off: Potency vs. Volume
As cells undergo repeated passages, they are not simply increasing in number – they are also experiencing cumulative biological changes.
Over time, cells in culture may demonstrate:
- Reduced responsiveness to environmental signals
- Altered differentiation potential
- Changes in gene expression profiles
- Shortened functional lifespan
This is not a binary shift, but a gradual one. Early passages tend to retain characteristics closer to the original cell population, while later passages may reflect adaptation to the artificial culture environment.
In regenerative medicine, this introduces a key tension:
Is a higher number of cells always better if those cells have undergone more expansion cycles?
The answer depends on how those cells are expected to function once introduced into the body.
Passage Expansion and Clinical Intent
Different regenerative strategies place different demands on cell behavior.
In protocols where signaling is the primary goal – such as modulating inflammation or influencing nearby cells – higher passage cells may still retain sufficient activity to contribute meaningfully.
But in cases where integration, differentiation, or long-term tissue interaction are important, the quality and functional integrity of the cells may carry more weight than sheer volume.
This is particularly relevant in applications involving:
- Joint degeneration
- Spine-related conditions
- Chronic musculoskeletal issues
In these scenarios, cells are expected to respond dynamically to the local environment. The degree to which they retain that responsiveness may be influenced by how extensively they have been expanded in culture.
Why Higher Passage Counts Are Common in the Market
From a market standpoint, higher passage expansion is not unusual. It reflects a combination of logistical, economic, and operational realities.
Laboratories operating at scale often prioritize:
- Consistent supply across multiple clinics
- Standardized production workflows
- Cost control within competitive pricing environments
Higher passage cells make these goals more achievable.
At the same time, patient-facing communication tends to focus on cell counts – a metric that is easy to understand but does not fully capture the underlying biology.
This can create a disconnect between what is being measured and what ultimately influences treatment behavior.
The Role of Cell Passage in Product Positioning
Cell passage is rarely highlighted in marketing materials, but it plays a quiet role in how different therapies are positioned.
Some protocols emphasize higher cell numbers, which may be associated with later passage expansion. Others focus on cell characteristics – such as viability, stress tolerance, or differentiation capacity – which may be more closely tied to earlier passages or specialized cell types.
For example, MUSE cells are often discussed in the context of stress-enduring behavior and selective differentiation. These characteristics are not solely defined by passage number, but they do raise broader questions about how cells are expanded and maintained prior to use.
The key point is not that one approach is inherently better, but that production method influences functional profile.
Cost Efficiency vs. Clinical Precision
The relationship between cost and quality in regenerative medicine is not always linear.
Higher passage expansion can lower production costs and increase availability. But it may also introduce variables that affect how cells behave in clinical settings.
This does not mean that higher passage cells are ineffective. Rather, it highlights the importance of aligning cell characteristics with treatment goals.
In practice, this alignment depends on:
- The condition being treated
- The delivery method used
- The expected role of the cells post-injection
A protocol designed for short-term signaling may tolerate different cell properties than one designed for long-term tissue interaction.
Delivery Method and Its Influence on Outcomes
The way cells are delivered can also shape how passage-related differences play out.
In many regenerative protocols, image-guided techniques – such as ultrasound or fluoroscopy – are used to place cells directly into a targeted area.
This precision can:
- Reduce variability in how cells interact with surrounding tissue
- Limit the need for systemic distribution
- Enhance the relevance of local cell behavior
When delivery is highly targeted, the functional quality of the cells may become more important than total quantity.
Conversely, in broader or systemic applications, the balance between volume and potency may shift.
Looking Beyond the Numbers
One of the more persistent themes in regenerative medicine is the emphasis on quantitative metrics – especially total cell count.
While these metrics provide a reference point, they do not capture:
- How cells were expanded
- How many passages they have undergone
- How they are expected to behave in vivo
This is where a more nuanced understanding becomes valuable.
Rather than asking only how many cells are being delivered, it can be useful to consider:
- What stage of expansion those cells represent
- How that expansion process may influence function
- Whether the protocol aligns with the intended clinical outcome
Passage Matters, Context Matters More
The use of higher cell passages is, in many ways, a reflection of scalability and cost management within the regenerative medicine industry. It allows laboratories to produce larger quantities of biologic material and make therapies more broadly available.
At the same time, cell passage is not just a production detail – it is a biological variable.
As cells are expanded through multiple passages, their characteristics may shift in ways that are relevant to how they function in treatment settings. This does not make higher passage cells inherently unsuitable, but it does introduce considerations that extend beyond simple cell counts.
Ultimately, the decision is not about choosing between “more” or “less,” but about understanding how production methods, biological behavior, and clinical intent intersect.
For patients evaluating treatment options, this reinforces a broader principle: regenerative medicine is most effective when therapies are selected based on mechanism and context, rather than metrics alone.
FAQ
What is cell passage in stem cell therapy?
Cell passage refers to the number of times cells have been expanded and re-cultured in a laboratory environment.
Why do higher passages reduce cost?
Higher passages increase the total number of cells produced from a single starting sample, lowering the cost per unit.
Do higher passage cells work the same as early passage cells?
They may function differently. Repeated expansion can influence responsiveness, differentiation potential, and signaling behavior.
Is a higher cell count always better?
Not necessarily. The effectiveness of treatment depends on how cells behave, not just how many are delivered.
Should patients ask about cell passage?
Understanding how cells are produced can provide additional context when comparing treatment options, especially alongside other factors like delivery method and clinical goals.
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.
Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.
Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.
© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.
